Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.
Shares of Silence Therapeutics SLN plunged 36.8% on Tuesday despite reporting positive end-of-treatment data from a mid-stage study of lead candidate, zerlasiran, to treat atherosclerotic ...
Silence Therapeutics PLC Sponsored ADR (SLN) shares soared 5.8% in the last trading session to close at $21.17. The move was backed by solid volume with far more shares changing hands than in a normal ...
Hosted on MSN
Wall Street Analysts Think Silence Therapeutics (SLN) Could Surge 556.19%: Read This Before Placing a Bet
Shares of Silence Therapeutics PLC Sponsored ADR (SLN) have gained 52% over the past four weeks to close the last trading session at $5.41, but there could still be a solid upside left in the stock if ...
Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results